Indication

Treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.

Medicine details

Medicine name:
lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
SMC ID:
SMC2517
Pharmaceutical company
Advanced Accelerator Applications
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC